Use of PDE inhibitor or salt thereof in preparation of medicament for preventing and / or treating gastrointestinal diseases

By using PDE inhibitors to improve cAMP levels, the problem of treatment of fibrosis diseases has been solved, and effective prevention and treatment of fibrosis in multiple organs has been achieved, especially in liver, gallbladder, gastrointestinal and lung diseases.

CN118903419APending Publication Date: 2024-11-08WOMEN & CHILDRENS MEDICAL CENTER AFFILIATED WITH GUANGZHOU MEDICAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410870179.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2020-02-10
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The pathogenesis of fibrotic diseases is unclear and difficult to treat. The prior art is difficult to effectively prevent and treat fibrotic diseases in multiple organs.

Method used

Increase cyclic adenosine phosphate (cAMP) levels by using phosphodiesterase inhibitors (PDE inhibitors), inhibit fibrosis, has anti-inflammatory and immune-regulating effects, and is used to prevent and treat liver, gastrointestinal tract, lungs, etc. Fibrosis disease.

Benefits of technology

Effectively inhibit fibrosis, improve the immune environment, reduce inflammation, delay organ damage, and provide new treatment options, especially in liver, gallbladder, gastrointestinal tract and lung diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004921387590000071
    Figure BDA0004921387590000071
  • Figure HDA0004921387610000011
    Figure HDA0004921387610000011
  • Figure HDA0004921387610000012
    Figure HDA0004921387610000012
Patent Text Reader

Abstract

The present invention relates to the use of a PDE inhibitor or a salt thereof for the preparation of a medicament for the prevention and / or treatment of gastrointestinal diseases. Through PDE inhibitors such as dipyridamole, the cAMP level can be improved to treat fibrotic diseases and inhibit fibrosis, and the pharmaceutical composition also has anti-inflammatory and immunoregulation effects and has a treatment effect on various links of occurrence and development of fibrosis.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of the Chinese application with application number 202010084911.2, filing date August 13, 2021, and invention name “Mechanism of fibrotic diseases and their therapeutic drugs”. Technical Field

[0002] The present invention relates to use of a PDE inhibitor or a salt thereof in preparing a medicament for preventing and / or treating gastrointestinal diseases. Background Art

[0003] Fibrosis is characterized by an increase in fibrous connective tissue and a decrease in parenchymal cells in organ tissues. It can occur in multiple organs. Continuous progression can lead to organ structural destruction and functional impairment, or even failure, which seriously threatens human health and life. Tissue fibrosis is the main cause of disability and death in many diseases worldwide, and plays an important role in the occurrence and development of diseases in major organs of the human body, such as the liver, cardiovascular system, lungs, and kidneys.

[0004] Specifically, fibrosis can be seen in hepatobiliary diseases, such as cirrhosis, liver fibrosis, liver damage, and biliary atresia (hereinafter sometimes referred to as BA). BA is a common disease that causes obstructive jaundice in infants and young children. In the perinatal period of infants and young children (for example, from 28 weeks of pregnancy to 4 weeks after birth), factors such as viral infection stimulate autoimmune reactions that cause pathological changes such as apoptosis or necrosis of bile duct epithelial cells, bile duct damage, inflammation and fibrosis, with poor prognosis and high mortality. The basic pathological changes of biliary atresia are, for example, progressive inflammation of the intrahepatic and extrahepatic bile ducts and liver fibrosis. The development of liver fibrosis is faster and more invasive than other adult diseases. Although the Kasai operation can partially relieve the symptoms of extrahepatic bile duct obstruction and delay the progression of the disease, most children still have progressive development of intrahepatic bile duct inflammation after surgery, which eventually leads to cirrhosis and portal hypertension, and even liver failure, which becomes a serious disease that endangers the life of children.

[0005] The incidence of gastrointestinal diseases, such as inflammatory bowel disease, undifferentiated colitis, Crohn's disease (hereinafter sometimes referred to as CD) and ulcerative colitis (hereinafter sometimes referred to as UC), is increasing year by year worldwide and is also a common clinical disease in China. Fibrosis can also be seen in gastrointestinal diseases. Gastrointestinal diseases cause acute attacks and persistent chronic subclinical inflammatory reactions or repeated attacks of the disease, which seriously affect the health and growth and development of a large number of patients, especially children, and also bring huge economic burdens to families and society.

[0006] Lung diseases, such as pulmonary fibrosis, silicosis, arterial hypertension and related diseases. Pulmonary fibrosis seriously affects the respiratory function of the human body, manifesting as dry cough and progressive dyspnea. As the disease and lung damage worsen, the patient's respiratory function continues to deteriorate. Idiopathic pulmonary fibrosis (IPF) is a fatal disease with a short survival time, few treatment options, and basically irreversible disease. Its fibrosis is characterized by the presence of activated fibroblasts, which produce excessive fibrous material that destroys the alveolar structure. The incidence and mortality of idiopathic pulmonary fibrosis are increasing year by year.

[0007] For a long time, the pathogenesis of fibrotic diseases has been unclear and difficult to treat. Summary of the invention

[0008] In order to solve the above problems, the inventors have conducted in-depth research on the pathogenesis of various fibrotic diseases, the dominant cells that cause the immune response, and their molecular mechanisms, and obtained the following results. The present invention can treat fibrotic diseases and inhibit the progression of fibrosis by increasing the level of cyclic adenosine monophosphate (hereinafter sometimes referred to as cAMP) by administering phosphodiesterase inhibitors (hereinafter sometimes referred to as PDE inhibitors). At the same time, the inventors have found that by administering PDE inhibitors, it also has anti-inflammatory and immunomodulatory effects, and has a therapeutic effect on all aspects of the occurrence and development of fibrosis.

[0009] The inventors have found that patients with liver fibrosis, such as patients with biliary atresia, all immune cell subtypes in the liver tissue express phosphodiesterase (hereinafter sometimes referred to as PDE), especially PDE4B. Therefore, the inventors improve the cAMP signaling pathway that is inhibited in liver damage by inhibiting the activity of PDE, increase the level of cAMP in the liver, improve the immune environment, fight inflammation, and inhibit fibrosis, thereby protecting the liver. The inventors use phosphodiesterase inhibitors (such as dipyridamole (hereinafter sometimes referred to as Dip)) to significantly inhibit the expression of fibroblast-related genes in in vitro cell experiments, and in the RRV virus-induced biliary atresia animal model, it can protect virus-infected mice from developing biliary atresia. Therefore, the use of PDE inhibitors to relieve the inhibition of the cAMP pathway caused by biliary atresia plays an important role in delaying liver damage and fibrosis, and PDE inhibitors (such as dipyridamole, etc.) can be used to treat and / or prevent the occurrence and development of hepatobiliary diseases such as biliary atresia.

[0010] The present inventors have also found that in patients with gastrointestinal diseases, such as various enteritis, there is a high infiltration of inflammatory macrophages, CD39 +IET deficiency and platelet aggregation defects, and defective cAMP response pathways work as a common mechanism. The inventors inhibited the activity of PDE, for example, by administering PDE inhibitors (such as dipyridamole, etc.), which can improve the suppressed cAMP signaling pathway in gastrointestinal diseases, improve the gastrointestinal immune environment, anti-inflammatory, and at the same time, inhibit gastrointestinal fibrosis, providing a new treatment plan for the prevention and treatment of gastrointestinal diseases.

[0011] The inventors further found that in lung diseases, PDE inhibitors (such as dipyridamole, etc.) can promote type I interferon signals and alleviate lung damage caused by viral infection. In in vitro cell tests, the addition of PDE inhibitors such as dipyridamole significantly promoted the mRNA and protein levels of cell IFN-; in a mouse model, it was shown that the lung inflammatory cell infiltration of mice after dipyridamole treatment was significantly reduced, and alveolar damage was alleviated. These results all show that PDE inhibitors (such as dipyridamole, etc.) have an effective effect on the prevention and treatment of lung inflammation, immunomodulation and fibrosis.

[0012] As mentioned above, the present invention relates to the following aspects:

[0013] [1]. A method for preventing and / or treating fibrotic diseases, comprising administering a PDE inhibitor to a subject.

[0014] [2] The method described in [1] above, wherein the PDE inhibitor is selected from the group consisting of PDE1, PDE2, PDE3, PDE4, PDE5, PDE6, PDE7, PDE8, PDE9, PDE10, and PDE11 inhibitors.

[0015] [3] The method according to any one of [1] to [2] above, wherein the PDE inhibitor is a PDE pan inhibitor.

[0016] [4] The method according to any one of [1] to [3] above, wherein the PDE inhibitor is dipyridamole.

[0017] [5] The method described in any one of [1] to [4] above, wherein the fibrotic disease is selected from fibrotic diseases of the liver, gallbladder, lung, kidney, bladder, heart, blood vessels, eyes, skin, pancreas, gastrointestinal tract, bone marrow, penis, breast, and muscle.

[0018] [6] The method according to any one of [1] to [5] above, wherein the fibrotic disease is selected from fibrotic diseases of the liver, gallbladder, lung, and gastrointestinal tract.

[0019] [7] The method according to any one of [1] to [6] above, wherein the fibrotic disease is selected from cirrhosis, liver fibrosis, liver damage, liver failure, and biliary atresia.

[0020] [8] The method according to any one of [1] to [7] above, wherein the fibrotic disease is selected from idiopathic pulmonary fibrosis, silicosis, cystic fibrosis, and arterial hypertension.

[0021] [9] The method described in any one of [1] to [8] above, wherein the fibrotic disease is selected from fibrosis of the stomach, duodenum, small intestine or colon, for example, colitis, undifferentiated colitis, Crohn's disease, ulcerative colitis, chronic colitis, chronic eosinophilic colitis.

[0022]

[10] . Use of PDE inhibitors in the preparation of medicaments for preventing and / or treating fibrotic diseases.

[0023]

[11] . The use described in

[10] above, wherein the PDE inhibitor is selected from PDE1, PDE2, PDE3, PDE4, PDE5, PDE6, PDE7, PDE8, PDE9, PDE10, and PDE11 inhibitors.

[0024]

[12] . The use according to any one of

[10] to

[11] above, wherein the PDE inhibitor is a pan-PDE inhibitor.

[0025]

[13] . The use according to any one of

[10] to

[12] above, wherein the PDE inhibitor is dipyridamole.

[0026]

[14] The use described in any one of

[10] to

[13] above, wherein the fibrotic disease is selected from fibrotic diseases of the liver, gallbladder, lung, kidney, bladder, heart, blood vessels, eyes, skin, pancreas, gastrointestinal tract, bone marrow, penis, breast, and muscle.

[0027]

[15] . The use described in any one of

[10] to

[14] above, wherein the fibrotic disease is selected from fibrotic diseases of the liver, gallbladder, lung, and gastrointestinal tract.

[0028]

[16] . The use described in any one of

[10] to

[15] above, wherein the fibrotic disease is selected from cirrhosis, liver fibrosis, liver damage, liver failure, and biliary atresia.

[0029]

[17] . The use according to any one of

[10] to

[16] above, wherein the fibrotic disease is selected from idiopathic pulmonary fibrosis, silicosis, cystic fibrosis, and arterial hypertension.

[0030]

[18] . The use described in any one of

[10] to

[17] above, wherein the fibrotic disease is selected from fibrosis of the stomach, duodenum, small intestine or colon, for example, colitis, undifferentiated colitis, Crohn's disease, ulcerative colitis, chronic colitis, chronic eosinophilic colitis.

[0031]

[19] A combination drug for treating a fibrotic disease as described in any one of [1] to [9] above, comprising a combination of a PDE inhibitor as described in any one of

[10] to

[18] above and other active ingredients, and a pharmaceutically acceptable carrier.

[0032]

[20] A pharmaceutical composition comprising the PDE inhibitor described in any one of

[10] to

[18] above, and a pharmaceutically acceptable carrier. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] Figure 1 It was shown that all immune cell subtypes in the liver tissue of patients with biliary atresia expressed PDE, especially PDE4B.

[0034] Figure 2 The PDE pan-inhibitor dipyrimidine (Dip) inhibits the expression of fibroblast genes. Figure 2 In the figure, the bars in each group of histograms are Nip (control), Dip, TGF-β, and TGF-β+Dip from left to right.

[0035] Figure 3 The figure shows that in the biliary atresia model caused by RRV infection of newborn mice, dipyridamole Dip protected virus-infected mice from developing biliary atresia. RRV-infected mice given Dip had a significant increase in weight (A) (in Figure A, the weight gain curve of the RRV group is at the bottom, the RRV+Dip group is in the middle, and the control group is at the top), and no jaundice occurred (B), indicating that Dip can prevent the occurrence of RRV-induced biliary atresia. HE staining of liver tissue found that liver necrosis and inflammatory cell infiltration foci in the Dip group mice were reduced (C), and Sirius red staining showed that liver fibrosis staining was significantly reduced (D).

[0036] Figure 4 The results show that in the biliary atresia model caused by RRV infection in newborn mice, dipyridamole Dip inhibited the replication of RRV virus in the liver. Non-structural protein 3 (NSP3) is involved in the replication of the virus in vivo. The results of qPCR in the liver tissue of mice showed that the level of NSP3 in the Dip group mice was significantly lower than that in the non-drug group (A), indicating that Dip can inhibit the invasion and toxic effects of the virus on the liver and protect the liver.

[0037] Figure 5 The results showed that the number of inflammation-related cells such as neutrophils and monocytes infiltrating the liver of RRV mice given Dip was reduced (A), and the mRNA levels of inflammatory factors TNF-α and IL-1β were significantly reduced (B).

[0038] Figure 6It shows that dipyridamole Dip promotes type I interferon signaling and alleviates lung injury caused by viral infection. (A) The mRNA level of IFN-b was detected by fluorescent quantitative PCR; the level of IFN-β in the supernatant was detected by ELISA. In Figure A, the left bar in each group of bar graphs represents the DMSO group, and the right bar represents the DIP group. (B) The phosphorylation levels of kinase TBK1 and transcription factor IRF3 were detected by Western blotting. (C) The mRNA level of IFN-b was detected by fluorescent quantitative PCR. (D) H&E staining of mouse lungs.

[0039] Figure 7 The results show that dipyridamole alleviates colitis fibroblast proliferation in mice and clinical experiments. (A) Immunofluorescence staining of frozen sections of mouse colon. (B) Immunofluorescence of colon from (A), blue is nucleus, red (upper: COL1A2; lower: CD90, both are indicators of fibroblasts). Control: N = 3; cDSS + DIP (chronic colitis DIP treatment) group: N = 3; cDSS + vehicle (chronic colitis control) group: N = 3. (C) Immunofluorescence (red: COL1A2, blue: nucleus) results of paraffin sections of the control group (normal colon) (N = 4), DIP-Before and DIP-After (before and after DIP treatment) (N = 7, Colitis is chronic colitis N = 3, EOS is chronic eosinophilic colitis N = 3, IBDu is undefined inflammatory bowel disease N = 1). The right side is the quantitative comparison of the difference in the number of fibroblasts among the three groups by immunofluorescence on the left. ****: P<0..0001; ***: P<0.001. DETAILED DESCRIPTION

[0040] The fibrosis of the present invention has the meaning known in the art, and is often manifested as an increase in fibrous connective tissue and a decrease in parenchymal cells in organ tissues. The meaning of fibrosis covers fibrosis of various tissues and organs, including but not limited to liver, gallbladder, lung, kidney, bladder, heart, blood vessels, eyes, skin, pancreas, gastrointestinal tract, bone marrow, penis, breast, muscle, etc.

[0041] For example,

[0042] Hepatobiliary fibrosis includes, for example, cirrhosis, liver fibrosis, liver damage, liver failure, biliary atresia, etc.;

[0043] Pulmonary fibrosis includes, for example, idiopathic pulmonary fibrosis (IPF), silicosis, cystic fibrosis (CF), hypertension (PH) and related diseases;

[0044] Gastrointestinal fibrosis includes fibrosis involved in gastrointestinal diseases, such as colitis, undifferentiated (also called indeterminate) colitis, Crohn's disease, ulcerative colitis, chronic colitis, chronic eosinophilic colitis and other inflammatory bowel diseases. The gastrointestinal tract described in the present invention includes the stomach, duodenum, small intestine, colon and other gastrointestinal tracts.

[0045] Muscle fibrosis includes, for example, muscular dystrophy;

[0046] Renal fibrosis includes, for example, tubulointerstitial fibrosis (TIF), renal interstitial fibrosis, and the like.

[0047] It should be understood by those skilled in the art that the fibrosis of the present invention also includes fibrotic tumors and cancers.

[0048] Hepatobiliary

[0049] Regarding hepatobiliary fibrosis, the inventors have conducted in-depth research and experiments on the pathogenesis of biliary atresia, the dominant cells that cause the immune response and their molecular mechanisms, which have shown that PDE inhibitors can relieve the inhibition of the cAMP pathway caused by biliary atresia, play an important role in delaying liver damage and fibrosis, and can also inhibit the occurrence and development of inflammation, inhibit the replication of viruses in the liver, and can effectively improve the damage caused by biliary atresia.

[0050] Specifically, PDE expression is widely present in various immune cell subtypes in the liver tissue of patients with biliary atresia. This provides a target for the use of PDE inhibitors in biliary atresia. In in vitro cell experiments, PDE inhibitors such as dipyridamole were used to stimulate and found that the expression level of fibroblast-related genes in the liver stellate cell line was significantly reduced. In the RRV virus-induced biliary atresia animal model, dipyridamole was given to protect the virus-infected mice from developing biliary atresia, without jaundice, and liver damage and fibrosis were reduced. It is worth noting that the expression level of NSP3, a molecule that reflects the replication of the virus in vivo, was significantly reduced in the liver of mice using PDE inhibitors such as dipyridamole, suggesting that PDE inhibitors protect the liver from viral invasion and toxicity. In addition, after the administration of PDE inhibitors, the infiltration of inflammatory cells and the expression of inflammatory factors in the liver of mice with RRV virus-induced biliary atresia were significantly reduced.

[0051] The new discovery of the present invention that liver immune cells of patients with biliary atresia express multiple PDEs provides a new treatment method for biliary atresia using PDE inhibitors, and also provides new medical uses for PDE inhibitors, which can be used to treat biliary atresia.

[0052] In the absence of specific treatment measures and with a high mortality rate, the use of PDE inhibitors such as biliary atresia to delay liver damage caused by biliary atresia, improve survival status, and treat biliary atresia has important scientific significance and clinical application value.

[0053] Gastrointestinal

[0054] Regarding gastrointestinal fibrosis, the inventors found that PDE inhibitors such as dipyridamole alleviated the proliferation of colitis fibroblasts in mice and clinical experiments. The results showed that the number of fibroblasts in the colon of chronic colitis mice injected with dipyridamole was significantly downregulated; the number of fibroblasts in the colon of children treated with PDE inhibitors such as dipyridamole was significantly downregulated. This suggests that PDE inhibitors such as dipyridamole can effectively treat gastrointestinal fibrosis.

[0055] In addition, the inventors have also discovered through experiments that, for example, PDE1, PDE4, PDE8 inhibitors can prevent and treat weight loss in mice with chronic colitis.

[0056] lung

[0057] Regarding pulmonary fibrosis, the inventors found that PDE inhibitors such as dipyridamole, etc., in in vitro cell tests infected by SeV virus, the addition of PDE inhibitors such as dipyridamole significantly promoted the mRNA and protein levels of cellular IFN-β; in a mouse model infected by RNA virus VSV, it was shown that the lung inflammatory cell infiltration of mice after dipyridamole treatment was significantly reduced, and alveolar damage was alleviated. These results all show that PDE inhibitors such as dipyridamole are effective in preventing and treating lung inflammation, immunomodulation and fibrosis. The inventors also found in experiments that PDE3 inhibitors and PDE5 inhibitors can significantly promote the mRNA and protein levels of cellular IFN-β.

[0058] The inventors have found that dipyridamole, a pan-PDE inhibitor, has a good inhibitory effect on fibrosis in fibrotic diseases of multiple organs and tissues such as the liver and gallbladder, gastrointestinal tract, and lungs, and can also fight inflammation and improve the immune environment. This provides an important idea for the application of pan-PDE inhibitors and suggests their role in various fibrotic diseases.

[0059] In the present invention, patients or subjects of fibrotic diseases are not limited by age and gender, and can be children, adults, and the elderly, wherein children can be, for example, newborns to 12 years old, 1-6 years old, etc. The subjects of the drug for treating fibrotic diseases of the present invention can also be other mammals, such as monkeys, cows, horses, pigs, mice, rats, hamsters, rabbits, cats, dogs, sheep, goats, etc.

[0060] The treatment of the present invention also includes prevention, such as administering the drug of the present invention to patients who are expected to have a high risk of developing the disease due to some disease-related factors but have not yet developed the disease, or to patients who have already developed the disease but have no subjective symptoms, or to patients who are afraid of recurrence of the disease after treatment.

[0061] The phosphodiesterase described in the present invention has the meaning known in the art. As known in the art, phosphodiesterase has the function of hydrolyzing intracellular second messengers (cAMP, cyclic adenosine monophosphate or cGMP, cyclic guanosine monophosphate), degrading intracellular cAMP or cGMP, thereby terminating the biochemical effects conducted by these second messengers.

[0062] The meaning of the phosphodiesterase inhibitor in the present invention is as known in the art. As known in the art, the phosphodiesterase family includes PDE1, PDE2, PDE3, PDE4, PDE5, PDE6, PDE7, PDE8, PDE9, PDE10, PDE11, etc., each of which has multiple isoenzyme subtypes, for example, PDE4 includes subtypes such as PDE4A, 4B, 4C and 4D.

[0063] The phosphodiesterase inhibitors of the present invention include drugs that inhibit any one or more of the phosphodiesterase family, including selective or non-selective phosphodiesterase inhibitors. Including but not limited to PDE1 inhibitors, PDE2 inhibitors, PDE3 inhibitors, PDE4 inhibitors, PDE5 inhibitors, PDE6 inhibitors, PDE7 inhibitors, PDE8 inhibitors, PDE9 inhibitors, PDE10 inhibitors, PDE11 inhibitors, or inhibitors with inhibitory effects on multiple members of the family and drugs that have inhibitory effects on other members of the phosphodiesterase family. Preferably, inhibitors with inhibitory effects on PDE1, and / or PDE3, and / or PDE4, and / or PDE5, and / or PDE8 are preferred. In the present invention, inhibitors that have inhibitory activity on multiple PDE subtypes are sometimes referred to as PDE pan-inhibitors, also known as non-specific PDE inhibitors, such as dipyridamole, which is known to have effects on multiple subtypes such as PDE5, PDE3, PDE4, and PDE2.

[0064] Specifically, the phosphodiesterase inhibitors of the present invention are not particularly limited as long as they have an inhibitory effect on phosphodiesterase, and are known to include nimodipine, vinpocetine, IC86340, IC224, EHNA, BAY60-7750, IC933, dipyridamole, cilostazol, cilostamide, milrinone, amrinone, enoximone, cyanoguanidine, theophylline, rolipram, pyramilast, roflumilast, cilomilast, apremilast, sildenafil, vardenafil, tadalafil, mitralin, udenafil, BRL-50481, IC242, and quinazoline and thiadiazole small molecule compounds S14 and VP1.15 discovered based on computer simulation, as well as other drugs that inhibit PDE. Among them, PDE3 inhibitors: Milrinone, Amrinone, Cilostazol, etc., PDE7 inhibitors: IC242, BRL50481, etc., PDE6 inhibitors: Sildenafil, etc., PDE4 inhibitors: Cilomilast, Rolipram, etc., PDE12 inhibitors: PDE12-IN-3, etc., and PDE pan inhibitors: Theophylline, Dipyridamole (sometimes referred to as Dip), Rottlerin, etc.

[0065] Dipyridamole

[0066]

[0067] Those skilled in the art will appreciate that the form of the active ingredient in each fibrotic disease drug described in the present invention is not limited, and may be in various forms such as the active compound itself, free state, salt, ester, isomer, optical isomer, stereoisomer, regioisomer, geometric isomer, hydrate, non-hydrate, solvate or non-solvate, amorphous, crystal, pharmaceutically acceptable co-crystal or co-crystal salt, derivative, prodrug, etc. Prodrugs include compounds that can be converted into the active ingredient due to the reaction of enzymes, gastric acid, etc. in an organism under physiological conditions, that is, compounds that can be converted into active ingredients by enzyme oxidation, reduction, hydrolysis, etc.; compounds that can be converted into active ingredients by hydrolysis, etc. due to gastric acid, etc. Co-crystals or co-crystal salts refer to crystalline substances composed of two or more specific substances, each of which is solid at room temperature and has different physical properties (e.g., structure, melting point, heat of fusion, hygroscopicity, solubility, stability, etc.). Co-crystals and co-crystal salts can be prepared using co-crystallization methods known per se.

[0068] For example, the active ingredients of the phosphodiesterase inhibitors (such as dipyridamole, etc.) in the present invention are not limited in form and can be in various forms such as the active compound itself, free state, salt, ester, isomer, optical isomer, stereoisomer, regioisomer, geometric isomer, hydrate, non-hydrate, solvate or non-solvate, amorphous, crystal, pharmaceutically acceptable co-crystal or co-crystal salt, derivative, prodrug, etc.

[0069] In the present invention, when referring to an active ingredient, it is intended to cover the above-mentioned various forms of the active ingredient. For example, when referring to dipyridamole, it is intended to cover the above-mentioned various forms of dipyridamole, including but not limited to free form, esters, salts, derivatives, prodrugs and other modified forms.

[0070] In the present invention, when the active ingredient is a salt, examples of such salts include metal salts, ammonium salts, salts formed with organic bases, salts formed with inorganic acids, salts formed with organic acids, salts formed with basic or acidic amino acids, and the like. Preferred examples of metal salts include: alkali metal salts, such as sodium salts, potassium salts, and the like; alkaline earth metal salts, such as calcium salts, magnesium salts, barium salts, and the like; and aluminum salts. Preferred examples of salts formed with organic bases include salts formed with the following organic bases: trimethylamine, triethylamine, pyridine, picoline, 2,6-lutidine, ethanolamine, diethanolamine, triethanolamine, cyclohexylamine, dicyclohexylamine, N,N'-dibenzylethylenediamine, and the like. Preferred examples of salts formed with inorganic acids include: salts formed with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, and the like. Preferred examples of the salt with an organic acid include salts with formic acid, acetic acid, trifluoroacetic acid, phthalic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, and the like. Preferred examples of the salt with a basic amino acid include salts with arginine, lysine, ornithine, and the like. Preferred examples of the salt with an acidic amino acid include salts with aspartic acid, glutamic acid, and the like.

[0071] Among these, pharmaceutically acceptable salts are preferred. For example, when the active ingredient contains an acidic functional group, examples thereof include inorganic salts, for example, alkali metal salts (for example, sodium salts, potassium salts, etc.), alkaline earth metal salts (for example, calcium salts, magnesium salts, etc.), ammonium salts, etc., and when the compound contains a basic functional group, examples thereof include salts formed with inorganic acids, for example, hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, etc., and salts formed with organic acids, for example, acetic acid, phthalic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, etc.

[0072] For example, the phosphodiesterase inhibitor of the present invention can be in free form, salt form, ester form, and various other derivatives, prodrugs and other modified forms. For example, in the case of dipyridamole, it can be in free form, ester, salt, derivative, prodrug and other modified forms.

[0073] The PDE inhibitor for fibrotic diseases described in the present invention can be administered in the form of its active compound itself or in the form of a mixture of the active compound and a pharmaceutically acceptable carrier.

[0074] As pharmaceutically acceptable carriers, various organic or inorganic carrier substances commonly used as preparation raw materials can be used, without particular limitation, and can be formulated in the form of excipients, lubricants, binders, disintegrants in solid preparations; solvents, solubilizers, suspending agents, isotonic agents, buffers, analgesics, etc. in liquid preparations. In addition, preparation additives such as preservatives, antioxidants, stabilizers, colorants, sweeteners, etc. can also be used as needed.

[0075] The preparation form of the PDE inhibitor of the present invention for fibrotic diseases is not particularly limited, and can be used as a drug for non-oral administration or oral administration, for example, in the form of liposomes or exosomes. The drug of the present invention can be any of solid preparations such as powders, granules, tablets or capsules, or liquid preparations such as syrups or emulsions. Drugs for treating gastrointestinal diseases can be safely administered in the following forms (for example, intravenous, intramuscular, subcutaneous, intra-organ, intranasal, intradermal, drops, intracerebral, rectal, vaginal, intraperitoneal, inside tumors, proximal tumors, lesions, etc.): tablets (including sugar-coated tablets, film-coated tablets, sublingual tablets, orally disintegrating tablets, buccal tablets, etc.), pills, powders, granules, capsules (including soft capsules, microcapsules), lozenges, syrups, liquids, emulsions, suspensions , controlled release preparations (e.g., immediate release preparations, sustained release preparations, sustained release microcapsules), aerosols, films (e.g., orally disintegrating films, oral mucosal adhesive films), injections (e.g., subcutaneous injections, intravenous injections, intramuscular injections, intraperitoneal injections), intravenous infusions, transdermal preparations, creams, ointments, lotions, adhesive preparations, suppositories (e.g., rectal suppositories, vaginal suppositories), granules, nasal preparations, pulmonary preparations (e.g., inhalants), eye drops, and the like.

[0076] The content of the PDE inhibitor of the present invention in the pharmaceutical composition varies based on the dosage form, dosage, etc. of the compound of the present invention. For example, the content is in the range of about 0.1 to 100 wt%.

[0077] The dosage of the PDE inhibitor for fibrotic diseases in the present invention is not particularly limited, as long as it is a therapeutically effective amount. In this specification, the term "therapeutically effective amount" refers to an amount that brings a therapeutic effect to a subject, for example: in a subject to which the amount is administered, compared with a subject not administered the amount, the symptoms or state of the disease are alleviated, reduced, or eliminated, or the development of the symptoms or state of the disease is delayed or inhibited. The therapeutically effective amount can be appropriately determined by a doctor based on the age, weight, sex, and severity of the symptoms of the subject. For example, for children, 0.1-100 mg / kg / day, 1-50 mg / kg / day, 3-20 mg / kg / day, administered once a day or divided into several times.

[0078] The PDE inhibitor for treating fibrotic diseases of the present invention can be used in combination with other drugs. Such other drugs include: anti-atherosclerotic drugs, anti-thrombotic drugs, anti-heart failure drugs, anti-arrhythmic drugs, anti-hypertensive drugs, drugs for treating diabetes, drugs for treating diabetic complications, drugs for increasing HDL, anti-hyperlipidemia drugs, anti-obesity drugs, diuretics, anti-inflammatory agents, anti-gout drugs, chemotherapeutic agents, immunotherapeutic agents such as anti-TNF-α drugs, hormones such as glucocorticoid drugs, osteoporosis drugs, anti-dementia drugs, erectile dysfunction improving drugs, drugs for treating urinary incontinence and drugs for treating dysuria. These other drugs can be low molecular weight compounds or high molecular weight proteins, polypeptides, antibodies, vaccines, etc.

[0079] There is no restriction on the administration time of the PDE inhibitor for the treatment of fibrotic diseases of the present invention and the other drugs, and they can be administered to the patient simultaneously or in a staggered manner. The dosage of the other drugs can be appropriately determined based on the dosage used in the clinical situation, and can be appropriately determined according to the administration patient, administration route, target disease, symptom, combination drug, etc.

[0080] The PDE inhibitor for fibrotic diseases of the present invention can form a combination drug with the above-mentioned other active ingredients of the drug. The combination drug can be a single preparation with active ingredients in the same preparation, or multiple preparations with active ingredients in different preparations.

[0081] The present invention preferably has the following aspects.

[0082] The present invention preferably uses dipyridamole for preventing and / or treating fibrotic diseases, and its pharmaceutical use.

[0083] The present invention preferably uses the pan-PDE inhibitor for preventing and / or treating fibrotic diseases, and its pharmaceutical use.

[0084] The present invention preferably uses PDE1, PDE2, PDE3, PDE4, PDE5, and PDE8 inhibitors for preventing and / or treating fibrotic diseases, and their pharmaceutical uses.

[0085] The present invention preferably uses dipyridamole for preventing and / or treating liver or gallbladder fibrosis, and its pharmaceutical use.

[0086] The present invention preferably uses dipyridamole for preventing and / or treating biliary atresia, liver cirrhosis, chronic liver damage, liver failure, liver fibrosis, and its pharmaceutical use.

[0087] The present invention preferably uses the pan-PDE inhibitor for preventing and / or treating liver or biliary fibrosis diseases, in particular biliary atresia, cirrhosis, chronic liver damage, liver failure, liver fibrosis diseases, and its pharmaceutical use.

[0088] The present invention preferably uses the PDE1 inhibitor for preventing and / or treating liver or biliary fibrosis diseases, in particular biliary atresia, cirrhosis, chronic liver damage, liver failure, liver fibrosis diseases, and its pharmaceutical use.

[0089] The present invention preferably uses PDE2 inhibitors for preventing and / or treating liver or biliary fibrosis diseases, in particular biliary atresia, cirrhosis, chronic liver damage, liver failure, liver fibrosis diseases, and their pharmaceutical uses.

[0090] The present invention preferably uses PDE3 inhibitors for preventing and / or treating liver or biliary fibrosis diseases, in particular biliary atresia, cirrhosis, chronic liver damage, liver failure, liver fibrosis diseases, and their pharmaceutical uses.

[0091] The present invention preferably uses PDE4 inhibitors for preventing and / or treating liver or biliary fibrosis diseases, in particular biliary atresia, cirrhosis, chronic liver damage, liver failure, liver fibrosis diseases, and their pharmaceutical uses.

[0092] The present invention preferably uses PDE4B inhibitors for preventing and / or treating liver or biliary fibrosis diseases, in particular biliary atresia, cirrhosis, chronic liver damage, liver failure, liver fibrosis diseases, and their pharmaceutical uses.

[0093] The present invention preferably uses PDE5 inhibitors for preventing and / or treating liver or biliary fibrosis diseases, in particular biliary atresia, cirrhosis, chronic liver damage, liver failure, liver fibrosis diseases, and their pharmaceutical uses.

[0094] The present invention preferably uses PDE8 inhibitors for preventing and / or treating liver or biliary fibrosis diseases, in particular biliary atresia, cirrhosis, chronic liver damage, liver failure, liver fibrosis diseases, and their pharmaceutical uses.

[0095] The present invention preferably uses PDE3B, PDE7A, PDE6D, PDE4D, PDE4B, and PDE12 inhibitors for preventing and / or treating liver or biliary fibrosis diseases, in particular biliary atresia.

[0096] The present invention preferably uses dipyridamole for preventing and / or treating gastrointestinal fibrosis diseases, and its pharmaceutical use.

[0097] The present invention preferably uses dipyridamole for preventing and / or treating fibrosis of the stomach, duodenum, small intestine or colon, such as colitis, undifferentiated colitis, Crohn's disease, ulcerative colitis, chronic colitis, chronic eosinophilic colitis, and its pharmaceutical use.

[0098] The pan-PDE inhibitors of the present invention are preferably used for preventing and / or treating gastrointestinal fibrotic diseases, in particular fibrosis of the stomach, duodenum, small intestine or colon, such as colitis, undifferentiated colitis, Crohn's disease, ulcerative colitis, chronic colitis, chronic eosinophilic colitis, and their pharmaceutical uses.

[0099] The preferred PDE1 inhibitors of the present invention are used for preventing and / or treating gastrointestinal fibrosis diseases, especially fibrosis of the stomach, duodenum, small intestine or colon, such as colitis, undifferentiated colitis, Crohn's disease, ulcerative colitis, chronic colitis, chronic eosinophilic colitis, and their pharmaceutical uses.

[0100] The preferred PDE2 inhibitors of the present invention are used for preventing and / or treating gastrointestinal fibrotic diseases, especially fibrosis of the stomach, duodenum, small intestine or colon, such as colitis, undifferentiated colitis, Crohn's disease, ulcerative colitis, chronic colitis, chronic eosinophilic colitis, and their pharmaceutical uses.

[0101] The preferred PDE3 inhibitors of the present invention are used for preventing and / or treating gastrointestinal fibrotic diseases, especially fibrosis of the stomach, duodenum, small intestine or colon, such as colitis, undifferentiated colitis, Crohn's disease, ulcerative colitis, chronic colitis, chronic eosinophilic colitis, and their pharmaceutical uses.

[0102] The present invention preferably uses PDE4 inhibitors for preventing and / or treating gastrointestinal fibrosis diseases, in particular fibrosis of the stomach, duodenum, small intestine or colon, such as colitis, undifferentiated colitis, Crohn's disease, ulcerative colitis, chronic colitis, chronic eosinophilic colitis, and their pharmaceutical uses.

[0103] The preferred PDE4B inhibitors of the present invention are used for preventing and / or treating gastrointestinal fibrotic diseases, in particular fibrosis of the stomach, duodenum, small intestine or colon, such as colitis, undifferentiated colitis, Crohn's disease, ulcerative colitis, chronic colitis, chronic eosinophilic colitis, and their pharmaceutical uses.

[0104] The preferred PDE5 inhibitors of the present invention are used for preventing and / or treating gastrointestinal fibrotic diseases, in particular fibrosis of the stomach, duodenum, small intestine or colon, such as colitis, undifferentiated colitis, Crohn's disease, ulcerative colitis, chronic colitis, chronic eosinophilic colitis, and their pharmaceutical uses.

[0105] The present invention preferably uses PDE8 inhibitors for preventing and / or treating gastrointestinal fibrotic diseases, in particular fibrosis of the stomach, duodenum, small intestine or colon, such as colitis, undifferentiated colitis, Crohn's disease, ulcerative colitis, chronic colitis, chronic eosinophilic colitis, and their pharmaceutical uses.

[0106] The present invention preferably uses dipyridamole for preventing and / or treating pulmonary fibrosis, and its pharmaceutical use.

[0107] The present invention preferably uses dipyridamole for preventing and / or treating idiopathic pulmonary fibrosis, silicosis, or arterial hypertension, and its pharmaceutical use.

[0108] The present invention preferably uses the pan-PDE inhibitor for preventing and / or treating pulmonary fibrosis, in particular idiopathic pulmonary fibrosis, silicosis, or arterial hypertension, and its pharmaceutical use.

[0109] The present invention preferably uses the PDE1 inhibitor for preventing and / or treating pulmonary fibrosis, in particular idiopathic pulmonary fibrosis, silicosis, or arterial hypertension, and its pharmaceutical use.

[0110] The present invention preferably uses the PDE3 inhibitor for preventing and / or treating pulmonary fibrosis, in particular idiopathic pulmonary fibrosis, silicosis, or arterial hypertension, and its pharmaceutical use.

[0111] The present invention preferably uses the PDE4 inhibitor for preventing and / or treating pulmonary fibrosis, in particular idiopathic pulmonary fibrosis, silicosis, or arterial hypertension, and its pharmaceutical use.

[0112] The present invention preferably uses the PDE5 inhibitor for preventing and / or treating pulmonary fibrosis, in particular idiopathic pulmonary fibrosis, silicosis, or arterial hypertension, and its pharmaceutical use.

[0113] The present invention preferably uses the PDE8 inhibitor for preventing and / or treating pulmonary fibrosis, in particular idiopathic pulmonary fibrosis, silicosis, or arterial hypertension, and its pharmaceutical use.

[0114] Example

[0115] The present invention is further specifically explained below with reference to examples, but the present invention is not limited thereto.

[0116] Example 1: Single-cell sequencing and bioinformatics analysis of immune cells in liver tissue of children with biliary atresia

[0117] In order to study the mechanism of autoimmune liver damage in biliary atresia and explore the dominant cells and molecular mechanisms that cause the immune response, the present invention sorted the immune cells (CD45+) in the liver tissue of children with BA and performed single-cell sequencing and bioinformatics analysis.

[0118] 1. Collection of clinical specimens and data:

[0119] The medical history of children with biliary atresia and the control group, especially the laboratory test indicators related to liver damage, were obtained from the electronic medical record system of the hospital. Ethical Statement: This project has been approved by the Medical Ethics Committee of Guangzhou Women and Children's Medical Center. The experiments were conducted in accordance with the "International Ethical Guidelines for Research Involving Human Subjects" as stated in the "Declaration of Helsinki". Informed consent for the project research will be obtained from the patients or their legal guardians. Inclusion Criteria for Subjects: The subjects of this study were recruited from children undergoing hepatobiliary surgery in the Department of Hepatobiliary Surgery of Guangzhou Women and Children's Medical Center.

[0120] The control children and BA children were judged according to the following criteria:

[0121] (1) Control: Children aged 0-4 months with hepatobiliary diseases (e.g., choledochal cysts, liver tumors, and cholestasis) who required surgical treatment.

[0122] (2) Biliary atresia: In children aged 0-4 months with obstructive jaundice, BA is diagnosed by intraoperative cholangiography and / or liver biopsy.

[0123] (3) Exclusion criteria: (1) children with systemic inflammatory response syndrome or multisystem malformations; (2) children with unclear primary diseases; (3) children whose parents refused to participate in the study or whose parental authorization could not be obtained.

[0124] 2. Flow cytometry

[0125] First, venous blood (2 mL) was drawn for Ficoll density gradient centrifugation to isolate and count peripheral blood mononuclear cells (PBMC). 0.5 g of liver tissue was ground, filtered, and lysed to obtain single-cell suspensions and counted. PBMC and liver single-cell suspensions were washed twice with PBS containing 0.5% BSA and 0.5 mM EDTA and stained with various antibody combinations. Flow cytometry data were acquired on a FACS Aria Sorp system and analyzed using Flowjo 10.4 software. Immune cell staining will be performed using the following antibody combinations: T cell phenotype and function: CD45, CD3, CD8a, γδT, CD45RA, CD25, CD127, CD44, CD103, CD69, PD-1, CCR2, CCR6, CXCR5, CXCR3; B cell phenotype: CD45, CD19, CD27, IgD, IgM, IgG, IgA, CD38, CD138, CD10, CD21, CD23, FCRL4, CD83, etc. To detect cytokine secretion, 2×10 6 The cells were resuspended in a culture medium containing 10% fetal bovine serum and stimulated with phorbol ester (PMA), myosin and monensin in a 37°C incubator for 4-6 hours. The cells were collected, permeabilized, fixed, and stained to detect the expression of cytokines IFN-γ, IL-17, IL-10, IL-2, IL-4, and transcription factors FOXP3, T-bet, RUNX3, RORγt, etc.

[0126] 3. Immunofluorescence Staining

[0127] Take paraffin sections of liver tissue from controls and BA patients and dewax them in xylene, put them in water, heat-repair to expose antigens, wash them with PBS for 3 minutes, 3 times, add 1% normal goat serum to block at room temperature for 1 hour, remove the blocking solution, add Yikang directly, and keep moisturized at 4℃ overnight. Wash them twice with pre-cooled PBS, incubate the labeled secondary antibody at room temperature for 1 hour, and protect them from light. Wash them with PBS twice. Take pictures under a fluorescence microscope or a laser confocal microscope.

[0128] 4. Autoantibody ELISPOT test

[0129] 10μg / mL dsDNA, Chromatin, RNP, Ro / SSA autoantibodies were spread on 96-well filter plates overnight, washed with PBS, and blocked with 2% fetal bovine serum RPMI 1640 medium at room temperature for 2 hours. Flow-sorted B cells (2000-10,000) were spread on the plate and incubated in a 37°C incubator for 18-48 hours, washed with PBS, and incubated at room temperature for 2 hours with 1:1000 IgG secondary antibody, washed with PBS, and color developed for about 10 minutes. After color development, washed with PBS and dried in the dark overnight. The number of spots is the number of B cells producing autoantibodies.

[0130] 5.ELISA method to detect autoantibodies

[0131] Similar to ELISPOT, 10 μg / mL dsDNA, Chromatin, RNP, Ro / SSA autoantibodies were plated on PVA96-well plates overnight, washed with PBS, and blocked with 2% fetal bovine serum RPMI 1640 medium at room temperature for 2 hours. Samples (lavage fluid, culture supernatant, or plasma) were added and incubated at room temperature for 2 hours, washed with PBS, and incubated with secondary antibodies for 2 hours, and finally developed for about 20 minutes. After color development, the absorbance at 405 nm was measured with an enzyme reader.

[0132] The results of single-cell sequencing of the liver of BA patients showed that PDE3B, PDE7A, PDE6D, PDE4D, PDE4B, and PDE12 were expressed in the liver immune cells of BA patients, among which PDE4B was the most widely expressed (see Figure 1 ). Based on the results of single-cell sequencing of the liver of patients with biliary atresia, it was found that various immune cell subtypes in the liver of patients with biliary atresia expressed multiple types of PDEs (see Figure 1 ), especially PDE4B is more widely expressed in various immune cells, suggesting that inhibiting the activity of PDE can relieve the inhibition of the cAMP pathway and increase the level of cAMP in the liver, thereby protecting the liver. This suggests that inhibiting the activity of PDE can relieve the inhibition of the cAMP pathway and increase the level of cAMP in the liver, thereby protecting the liver.

[0133] Example 2: PDE inhibitor dipyridamole inhibits the expression of fibroblast genes

[0134] In vitro cell culture: The human hepatic stellate cell line LX-2 was cultured in vitro and divided into a control group (Nli), a dipyridamole (Dip) (4 μM) group, a cytokine TGF-β (5 ng / mL) group, and a cytokine TGF-β (5 ng / mL) + dipyridamole (Dip) (4 μM) group. The experiment was carried out for 3 days, and the cells were collected to extract RNA, which was reverse transcribed into cDNA and then qPCR was performed to detect the expression of fibroblast genes.

[0135] The results showed that after the in vitro culture of the hepatic stellate cell line LX-2, stimulated by Dip, the qPCR results showed that the basal levels of fibrosis-related genes α-SMA, COLL1A1, COLL1A2, and COLL3A1 were significantly suppressed. After being activated by the cytokine TGF-β, the expression of the above genes was also suppressed by Dip (see Figure 2 ).like Figure 2 As shown in the figure, Dip significantly inhibited the expression of fibroblast genes α-SMA, COLL1A1, COLL1A2, and COLL3A1. Under the condition of cytokine TGF-β stimulation, Dip can still play a role in inhibiting the expression of fibroblast genes.

[0136] Example 3: Experimental study on the effect of PDE inhibitor dipyridamole on biliary atresia

[0137] 1. Establishment of animal model of biliary atresia:

[0138] (1) Animals: Adult BALB / c pregnant mice, specific pathogen-free (SPF) grade, were purchased from Guangdong Medical Laboratory Animal Center. They were kept in the SPF grade environment of the Laboratory Animal Center of Guangzhou Medical University. The pregnant mice gave birth to newborn mice (each pregnant mouse gave birth to an average of 8 newborn mice), with an average weight of 1.5 g. Newborn mice were randomly selected for the experiment according to the experimental groups. The animal handling method of this experiment complies with animal ethics standards.

[0139] (2) Modeling method: Newborn BALB / c mice were intraperitoneally injected with 20 μL of monkey MMU18006 rotavirus (titer 1.0×10 6 PFU) to establish the BA mouse animal model. The detailed steps are shown in the previously published article "Comparison of hepatobiliary damage of newborn mice by rotavirus of different titers. Chinese Journal of Experimental and Clinical Virology. 2017.01.1003-9279", all of which are cited here as reference.

[0140] (3) Observe the survival status of mice: including mouse survival rate, growth weight, skin jaundice and changes in liver function.

[0141] (4) Immune cell and cytokine detection: Immunofluorescence and flow cytometry techniques were used to detect PD-1 in liver tissue of this project. + T cells, CD21 - The expression of B cells. For detailed steps, please refer to the previous article "Zhang R. Nanomedicine: nanotechnology, biology, and medicine, 2017, 13 (3): 1041-1050.", all of which are cited here as reference.

[0142] In the established acute biliary atresia mouse model, dipyridamole was injected intraperitoneally before rotavirus (RRV) injection at birth. Paired experiments were performed according to experimental requirements, and the BA model was divided into different experimental groups: 1) control mouse group, 2) BA mouse model group, 3) BA mouse + solvent group, 4) BA mouse + Dip group (where Dip, 50 μg per 2g body weight, intraperitoneal injection, supplementary administration on the 3rd, 6th, and 9th days after RRV virus injection, and the experiment was terminated on the 12th day). The hepatobiliary appearance, jaundice characteristics and survival rate of the above groups of mice were observed, and the number of inflammatory cell infiltration in the liver tissue was detected; the cytokines (IL-6, IL-8, IL-10, IL-1b, IL-18, IFN-γ, IL-17, IL-10, TNF-α, TGF-β, bFGF, PDGF and CTGF, etc.) that have been confirmed to be closely related to biliary atresia and fibrosis in the mouse hepatocyte suspension were detected, as well as the antibody subtype and autoantibody content.

[0143] The results show that: Figure 3-5 The PDE inhibitor dipyridamole (Dip) was used in the biliary atresia model caused by RRV infection in newborn mice. Figure 3 The results showed that Dip could increase the weight of mice (A) and did not cause jaundice (B), indicating that Dip could prevent the occurrence of RRV-induced biliary atresia; HE staining of liver tissue found that the liver necrosis and inflammatory cell infiltration foci in the Dip group mice were reduced (C), and Sirius red staining indicated that liver fibrosis staining was significantly reduced (D). Therefore, Dip protected the liver from RRV virus infection-induced liver damage and liver fibrosis, and reduced liver necrosis foci, inflammatory cell infiltration, and the secretion of inflammatory cytokines. Figure 4 The results showed that dipyridamole inhibited the replication of RRV in the liver. Non-structural protein 3 (NSP3) is involved in the replication of the virus in vivo. Figure 4 In the figure, the vertical axis represents the level of NSP3. The qPCR results of mouse liver tissue indicate that the level of NSP3 in the Dip group mice was significantly lower than that in the non-drug group, which indicates that Dip can inhibit the invasion and toxic effects of the virus on the liver and protect the liver. Figure 5 The results showed that the number of inflammatory-related cells such as neutrophils and monocytes infiltrating in the liver of RRV mice given Dip was reduced (A), and the mRNA levels of inflammatory factors TNF-α and IL-1β were significantly reduced (B). These results suggest that Dip has an inhibitory effect on liver inflammation caused by RRV virus infection.

[0144] Example 4: Experimental study on the effect of PDE inhibitors on pulmonary fibrosis

[0145] DIP and DMSO were added to lung epithelial A549 cells, and SeV (MOI = 1) was infected at the same time. The cells and culture supernatant were collected at 0, 16 and 24 hours of infection. Total RNA was extracted from the cells, and the mRNA level of IFN-b was detected by fluorescence quantitative PCR; the level of IFN-β in the supernatant was detected by ELISA. The addition of DIP significantly promoted the mRNA and protein levels of IFN-β in the cells (see Figure 6 A).

[0146] Different doses of DIP (0 mM, 4 mM, 20 mM) were added to 293T cells, and SeV was infected (MOI = 1). The cells were collected and the phosphorylation levels of kinase TBK1 and transcription factor IRF3 were detected by Western blotting (see Figure 6 B).

[0147] Different PDE inhibitors (DIP, etc.) (5 μM) and DMSO were added to lung epithelial cells A549, and SeV (MOI = 1) was infected for 24 hours. The cells were collected to extract total RNA, and the IFN-b mRNA level was detected by fluorescence quantitative PCR. PDE inhibitors can significantly increase the mRNA level of type I interferon IFN-b. (See Figure 6 C).

[0148] The mouse model of RNA virus VSV infection was constructed according to methods known in the art. The mice were intraperitoneally injected with 30 mg / kg of dipyridamole every day starting on day -3, and injected with 10 mg / kg of dipyridamole via the tail vein on days 0 and 4. 8 PFU / g of VSV, and continued to be administered for 7 days. H&E staining of the lungs of mice showed that the infiltration of inflammatory cells in the lungs of mice treated with DIP was significantly reduced, and the alveolar damage was alleviated. (See Figure 6 D).

[0149] The above results indicate that dipyridamole promotes type I interferon signaling and alleviates lung damage caused by viral infection.

[0150] Example 5: Experimental study on the effect of PDE inhibitor dipyridamole on gastrointestinal fibrosis

[0151] The mice were divided into three groups: the control group had normal diet and drinking water; the cDSS+DIP (chronic colitis DIP treatment) group was intraperitoneally injected with 100uL DIP (50mk / kg) on ​​the second day, twice a day until the 28th day; the cDSS+vehicle (chronic colitis control) group was intraperitoneally injected with the same volume of control solvent on the second day, also twice a day until the 28th day. At the same time, in the cDSS+DIP and cDSS+vehicle groups, normal drinking water was replaced with drinking water containing 2% DSS on days 0-7 and 21-28, and normal drinking water was used for the rest of the time. All groups took the mouse colon on day 28 for immunofluorescence staining of frozen sections.

[0152] (See Figure 7 A).

[0153] like Figure 7 B shows the colon immunofluorescence from the above, blue is the nucleus, red (upper: COL1A2; lower: CD90, both are indicators of fibroblasts). The results suggest that the number of fibroblasts in the colon of chronic colitis mice injected with DIP was significantly downregulated. Control: N = 3; cDSS + DIP (chronic colitis DIP treatment) group: N = 3; cDSS + vehicle (chronic colitis control) group: N = 3.

[0154] In the preliminary clinical experiment of DIP, the inventors divided the children into three groups: control group (normal colon) (N=4), DIP-Before and DIP-After (before and after DIP treatment) (N=7, Colitis is chronic colitis N=3, EOS is chronic eosinophilic colitis N=3, IBDu is undifferentiated inflammatory bowel disease N=1). Through the results of immunofluorescence of paraffin sections (red: COL1A2, blue: cell nucleus), it was found that the number of fibroblasts in the colon of children treated with DIP was significantly downregulated. The right side is the quantitative comparison of the difference in the number of fibroblasts among the three groups by immunofluorescence on the left. ****: P<0..0001; ***: P<0.001.

[0155] (See Figure 7 C).

[0156] The above results show that dipyridamole alleviates the proliferation of colitis fibroblasts both in mice and in clinical trials in patients.

[0157] The present invention includes various changes in its scope, and these changes do not deviate from the scope of the present invention. In addition, all situations that are obviously considered to be variations of the present invention by those skilled in the art are included in the scope of the claims of the present invention.

Claims

1. Use of a PDE inhibitor or a salt thereof in the preparation of a medicament for preventing and / or treating gastrointestinal diseases; Preferably, the gastrointestinal disease is a fibrotic disease occurring in at least one of the stomach, duodenum, small intestine or colon.

2. The use according to claim 1, characterized in that The gastrointestinal diseases include colitis, Crohn's disease and colonic fibrosis; Preferably, the colitis includes undifferentiated colitis, ulcerative colitis, chronic colitis and chronic eosinophilic colitis.

3. The use according to claim 1, characterized in that The fibrosis includes fibrosis caused by undifferentiated colitis, Crohn's disease, ulcerative colitis, chronic colitis and chronic eosinophilic colitis.

4. The use according to claim 1, characterized in that The PDE inhibitor is selected from at least one of pan-PDE, PDE1, PDE2, PDE3, PDE4, PDE5, PDE6, PDE7, PDE8, PDE9, PDE10 and PDE11 inhibitors; Preferably, the PDE inhibitor is selected from at least one of pan-PDE, PDE1, PDE2, PDE3, PDE4 and PDE10 inhibitors.

5. The use according to any one of claims 1 to 4, wherein The PDE inhibitor is selected from dipyridamole, milrinone, cilostazol, and roflumilast; And / or, the salt includes a metal salt, an ammonium salt, or a salt formed by the PDE inhibitor with an organic base, an inorganic acid, an organic acid, or a basic or acidic amino acid.

6. The use according to any one of claims 1 to 4, characterized in that: The subjects of use of the medicine include children, adults or the elderly.

7. The use according to any one of claims 1 to 4, characterized in that: The dosage of the drug is 0.1 mg / kg / day to 100 mg / kg / day, preferably 1-50 mg / kg / day, more preferably 3-20 mg / kg / day.

8. The use according to any one of claims 1 to 4, characterized in that: The content of the PDE inhibitor or its salt in the drug is 0.1-100 wt %.

9. The use according to any one of claims 1 to 4, characterized in that: The drug is administered intravenously, intramuscularly, subcutaneously, intra-organically, intranasally, intradermally, by drops, intracerebrally, intrarectally, vaginally, intraperitoneally, intratumorally, proximal to a tumor, or focally.

10. The use according to any one of claims 1 to 4, characterized in that: The medicine includes oral administration dosage form and parenteral administration dosage form.

11. The use according to claim 10, characterized in that The dosage forms include: tablets, pills, powders, granules, hard capsules, soft capsules, microcapsules, lozenges, syrups, emulsions, solutions, suspensions, sustained-release preparations, aerosols, films, injections, transdermal patches, creams, ointments, lotions, adhesive preparations, suppositories or granules.

12. Use of the composition in the preparation of a medicament for preventing and / or treating gastrointestinal diseases; The composition comprises a PDE inhibitor or a salt thereof according to any one of claims 1 to 11, and a second drug; And optionally, the composition further comprises a pharmaceutically acceptable carrier.

13. The use according to claim 12, characterized in that The second drug includes anti-atherosclerotic drugs, anti-thrombotic drugs, anti-heart failure drugs, anti-arrhythmic drugs, anti-hypertensive drugs, drugs for treating diabetes, drugs for treating complications of diabetes, drugs for increasing HDL, anti-hyperlipidemia drugs, anti-obesity drugs, diuretics, anti-inflammatory agents, anti-gout drugs, chemotherapeutic agents, immunotherapeutic agents, hormone substances, osteoporosis drugs, anti-dementia drugs, erectile dysfunction improving drugs, drugs for treating urinary incontinence and drugs for treating dysuria; Preferably, the immunotherapeutic agent is an anti-TNF-α drug. Preferably, the hormone drug is a glucocorticoid drug.